Patient Perception Study for AL-4943A
Overview
To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: October 2011
Interventions
- Drug: AL-4943A
- Once daily topical ocular allergy medication used for 7 days
Arms, Groups and Cohorts
- Experimental: AL-4943A
- One drop per day in both eyes
Clinical Trial Outcome Measures
Primary Measures
- Overall Patient satisfaction
- Time Frame: 7 days
Participating in This Clinical Trial
Inclusion Criteria
- History of allergic conjunctivitis within last 24 months – Active signs and symptoms of ocular allergies Exclusion Criteria:
- Severe or serious ocular condition, ocular surgical intervention, ocular infection
Gender Eligibility: All
Minimum Age: 12 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Alcon Research
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.